Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis.
Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.
Age Related Macular Degeneration
Central Serous Chorioretinopathy
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Evaluation of Genetic Variants in Patients With Type 1 Neovascularization (Sub-retinal Pigment Epithelium Neovascularization) Who Lack Typical Findings of Age Related Macular Degeneration (AMD) But Present With Findings More Consistent With Long-standing Central Serous Chorioretinopathy (CSC).|
- Total genetic burden [ Time Frame: Baseline assessment ] [ Designated as safety issue: No ]The identification of individual genetic markers or a quantitative measure of total genetic burden associated with CNV secondary to CSC vs. CSC vs. CNV secondary to advanced AMD as meaured by the commercially available RetnaGene AMD assay.
Biospecimen Retention: Samples With DNA
|Study Start Date:||November 2012|
|Estimated Study Completion Date:||June 2014|
|Estimated Primary Completion Date:||June 2014 (Final data collection date for primary outcome measure)|
|CNV secondary to CSC|
|CSC without CNV|
|CNV secondary to advanced AMD|
To determine if patients presenting with type 1 neovascularization believed to be secondary to CSC are genetically distinct from typical CSC patients without neovascularization or patients presenting with choroidal neovascularization (CNV) secondary to advanced AMD. Disease associated markers detecting variants in ARMS 2, Complement Factor H (CFH) Complement component 3 (C3), Complement component 2 (C2) , Factor B (FB), VEGFA or other genetic polymorphisms associated with CNV will be evaluated to determine if the CSC neovascular group is genetically distinct from the CSC group without neovascularization or the advanced AMD group.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01880788
|Contact: Bailey Freund, MD||(212) email@example.com|
|United States, New York|
|Vitreous Retina Macula Consultants of New York||Recruiting|
|New York City, New York, United States, 10022|
|Contact: May Lee 212-452-6965 firstname.lastname@example.org|
|Principal Investigator: Bailey Freund, MD|